SAN Sanofi

Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

PARIS, France – March 4, 2021 - Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).

These documents are available on the company’s website: .

In addition, the Form 20-F is available on the website of the SEC () and the “Document d’Enregistrement Universel” is available on the website of the AMF (). A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request.

 



About Sanofi



 



Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.



 



With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.



 



Sanofi, Empowering Life



 





Media Relations Contact

Ashleigh Koss

Tel: +1 (908) 981-8745





 



Sandrine Guendoul

Tel.: +33 (0)1 53 77 46 46









 
 



Investor Relations Contacts Paris

Eva Schaefer-Jansen

Arnaud Delepine

Yvonne Naughton



 



Investor Relations Contacts North America

Felix Lauscher

Fara Berkowitz

Suzanne Greco



 



IR main line:

Tel.: +33 (0)1 53 77 45 45





 







 



Attachment



EN
04/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic g...

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight o...

 PRESS RELEASE

Communiqué de presse : Le Rezurock de Sanofi approuvé dans l’UE pour l...

Communiqué de presse : Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte Rezurock est maintenant approuvé dans l’UE pour les adultes et les enfants âgés de 12 ans et plus atteints de GvHD chronique, offrant ainsi un nouveau médicament aux patients disposant d’options thérapeutiques limitées. Paris, le 31 mars, 2026. La Commission européenne a accordé une autorisation de mise sur le marché conditionnelle pour Rezurock (belu...

Research Department
  • Research Department

INFORME DIARIO 30 MARZO (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: BANKINTER, BBVA. EUROPA: SANOFI. La entrada de los Hutíes empeora las perspectivas del conflicto en Oriente Medio Las bolsas se movieron durante la semana en un entorno de volatilidad, pendientes del conflicto en Oriente Medio después de que Trump volviera a ampliar el plazo hasta el 6 de abril para atacar infraestructuras energéticas en Irán. La entrada de las milicias Hutíes de Yemen, apoyadas por Irán, en el conflicto y sus posibles actuaciones e...

 PRESS RELEASE

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 stud...

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed either Q4W or Q12W, showed progressively increasing efficacy, with no evidence of plateau at Week 24 across endpointsData reinforce potential for Q12W dosing from the start Paris, March 28, 2026. Positive results from three phase 3 studies of amlitelimab, ...

 PRESS RELEASE

Communiqué de presse : AAD : Sanofi présente de nouveaux résultats de ...

Communiqué de presse : AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute Dans les études de phase 3 COAST 1, COAST 2 et SHORE, l’amlitelimab, administré 1x/4 sem. ou 1x/12 sem., a montré une augmentation progressive de l’efficacité, sans signe de plateau à la semaine 24 pour l’ensemble des critères d’évaluation.Les données confortent le potentiel d’une administr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch